ArticleBMC immunology2026
MiR-100-5p is involved in severe pneumonia in children by targeting MTOR.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere pneumonia in children is a life-threatening respiratory condition that can lead to severe complications and even mortality. We confirmed the possibility of miR-100-5p as a biomarker in severe pneumonia in children.
methodsA total of 200 children were included. The expression of miR-100-5p from serum was detected. WI-38 cells were treated with 10 µg/mL LPS for 24 h. miR-100-5p was overexpressed or inhibited by transfection. In addition, proliferation and inflammatory factors were measured. TargetScan was utilized to forecast the downstream of miR-100-5p. The targeting relationship between miR-100-5p and MTOR was confirmed by the dual-luciferase reporter system. miR-100-5p and MTOR were co-overexpressed to detect the function of both in severe pneumonia in children.
resultsmiR-100-5p expression was decreased and had a high diagnostic value in severe pneumonia in children. The miR-100-5p level was closely related to clinical indicators. In WI-38 cells treated with LPS, overexpression of miR-100-5p increased proliferation and reduced inflammatory factors, while inhibition of miR-100-5p reduced proliferation and increased inflammatory factors. MTOR expression was negatively associated with miR-100-5p expression in severe pneumonia in children.
conclusionsmiR-100-5p may participate in severe pneumonia in children by negatively regulating MTOR, proving that it might be a biomarker of severe pneumonia in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.